CJC-1295 and ipamorelin
CJC-1295 and ipamorelin approach growth-hormone release through different signals. We explain that idea, the small studies of the separate compounds and why the blend has no established benefit for sleep or recovery in people.
Perform Peptide may earn money when readers become Promise patients.
Two routes toward the same hormone conversation
Growth hormone is released by the pituitary, a small gland beneath the brain. CJC-1295 resembles part of growth hormone-releasing hormone, one of the brain’s signals to that gland. Ipamorelin acts at a different receptor, the receiving site used by ghrelin, a hormone involved in hunger. These are different signals, rather than two names for growth hormone itself.
The reason people discuss the pair is understandable: two signalling routes can be studied together. But that reasoning does not establish a recovery benefit for the fixed blend. The human evidence for its components is limited, and research on related combinations is not a trial of this particular product.
First, pin down what CJC-1295 means
The name is used for forms with and without DAC, a chemical attachment that binds a blood protein and extends the substance’s time in the body. Those forms are not interchangeable. The small CJC-1295 study in healthy adults involved the longer-acting DAC form and measured growth hormone and IGF-1, a growth-related signal influenced by growth hormone.
It did not establish better sleep, tissue recovery or performance. A change in a blood measurement is an intermediate finding: it says that a signal changed, not that a person had a useful change in daily life. It also cannot stand in for research on a different CJC-1295 form in a blend.
What ipamorelin’s human research asked
Ipamorelin’s published human work includes an early hormone study and a trial after bowel surgery. The surgical trial did not find a clear difference on its main measure. Neither study tested this blend for recovery after training or rehearsal, and neither establishes a sleep benefit.
The FDA’s ipamorelin assessment discusses the lack of safety information for the route commonly promoted outside those studies. An experiment in a hospital after surgery cannot define the risks of repeated use by otherwise healthy people. The setting, route and reason for treatment all matter.
Two FDA tables, different meanings
On the FDA page current as of April 22, 2026, ipamorelin acetate appears in both tables: nominated but withdrawn, and still in Category 2 under the 503B interim policy. Category 2 identifies significant safety concerns. Section 503B covers registered outsourcing facilities that compound medicines in batches. Withdrawal is not approval or clearance. FDA provides no individual withdrawal date on that page.
CJC-1295 is in the withdrawn-nomination table. The FDA’s CJC-1295 assessment also describes the ingredient and naming problems. Neither compound has an FDA-approved product, and the combination is not FDA-approved. The documented ingredient restrictions do not disappear because the two are placed together.
Safety and a real decision
FDA concerns include immune responses to the peptides or their impurities. CJC-1295 studies reported flushing, headache and local reactions, and FDA identifies heart-rate and blood-pressure concerns. Growth-hormone-related changes also bring questions about blood sugar and fluid retention. Long-term safety of this blend has not been established.
Promise Peptides lists the CJC-1295 and ipamorelin combination. A licensed U.S. provider reviews each request and decides whether any prescription is appropriate. Some people do not qualify, and the service is limited to U.S. patients with state and treatment differences.
Compounded CJC-1295 and ipamorelin preparations are not FDA-approved. The FDA assessments identify failures to meet the ingredient rules for ordinary pharmacy compounding under section 503A. A product listing does not establish a lawful route. Any proposed prescription needs an explicit explanation of its legal basis as well as its clinical rationale. The Promise listing concerns the combined preparation.
You can take questions about the exact CJC-1295 form, existing conditions, other medicines and the purpose of any monitoring into a provider conversation. This guide cannot translate a hormone value into a personal treatment choice. The comparison can help keep this blend separate from sermorelin and tesamorelin before that discussion.